Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue.

Details

Ressource 1Download: 23069623.pdf (2139.67 [Ko])
State: Public
Version: Final published version
License: CC BY-NC-ND 4.0
Serval ID
serval:BIB_F89B0401188B
Type
Article: article from journal or magazin.
Collection
Publications
Title
Inhibition of class I histone deacetylases unveils a mitochondrial signature and enhances oxidative metabolism in skeletal muscle and adipose tissue.
Journal
Diabetes
Author(s)
Galmozzi A., Mitro N., Ferrari A., Gers E., Gilardi F., Godio C., Cermenati G., Gualerzi A., Donetti E., Rotili D., Valente S., Guerrini U., Caruso D., Mai A., Saez E., De Fabiani E., Crestani M.
ISSN
1939-327X (Electronic)
ISSN-L
0012-1797
Publication state
Published
Issued date
2013
Peer-reviewed
Oui
Volume
62
Number
3
Pages
732-742
Language
english
Abstract
Chromatin modifications are sensitive to environmental and nutritional stimuli. Abnormalities in epigenetic regulation are associated with metabolic disorders such as obesity and diabetes that are often linked with defects in oxidative metabolism. Here, we evaluated the potential of class-specific synthetic inhibitors of histone deacetylases (HDACs), central chromatin-remodeling enzymes, to ameliorate metabolic dysfunction. Cultured myotubes and primary brown adipocytes treated with a class I-specific HDAC inhibitor showed higher expression of Pgc-1α, increased mitochondrial biogenesis, and augmented oxygen consumption. Treatment of obese diabetic mice with a class I- but not a class II-selective HDAC inhibitor enhanced oxidative metabolism in skeletal muscle and adipose tissue and promoted energy expenditure, thus reducing body weight and glucose and insulin levels. These effects can be ascribed to increased Pgc-1α action in skeletal muscle and enhanced PPARγ/PGC-1α signaling in adipose tissue. In vivo ChIP experiments indicated that inhibition of HDAC3 may account for the beneficial effect of the class I-selective HDAC inhibitor. These results suggest that class I HDAC inhibitors may provide a pharmacologic approach to treating type 2 diabetes.
Keywords
Adipose Tissue/cytology, Adipose Tissue/drug effects, Animals, Anti-Obesity Agents/pharmacology, Anti-Obesity Agents/therapeutic use, Cell Line, Cells, Cultured, Diabetes Mellitus, Type 2/complications, Diabetes Mellitus, Type 2/drug therapy, Energy Metabolism/drug effects, Gene Expression Regulation/drug effects, Histone Deacetylase 1/antagonists & inhibitors, Histone Deacetylase 1/metabolism, Histone Deacetylase 2/antagonists & inhibitors, Histone Deacetylase 2/metabolism, Histone Deacetylase Inhibitors/pharmacology, Histone Deacetylase Inhibitors/therapeutic use, Hypoglycemic Agents/pharmacology, Hypoglycemic Agents/therapeutic use, Male, Mice, Mice, Mutant Strains, Mitochondria, Muscle/drug effects, Mitochondria, Muscle/metabolism, Molecular Targeted Therapy, Muscle, Skeletal/drug effects, Muscle, Skeletal/metabolism, Obesity/complications, Obesity/drug therapy, Random Allocation
Pubmed
Web of science
Open Access
Yes
Create date
15/02/2015 21:43
Last modification date
17/02/2020 17:27
Usage data